Amneal Pharmaceuticals (AMRX) Notes Payables (2018 - 2024)

Amneal Pharmaceuticals' Notes Payables history runs 5 years deep, the most recent figure standing at $41.9 million for Q1 2024.

• On a quarterly basis, Notes Payables changed N/A year-over-year to $41.9 million in Q1 2024; TTM through Mar 2024 was $41.9 million, a N/A change from a year earlier, with the FY2023 full-year figure at $41.4 million, up 4.38% from the prior year.
• Notes Payables improved to $41.9 million in Q1 2024 per AMRX's latest filing, from $41.4 million in the prior quarter.
• Across five years, Notes Payables topped out at $41.9 million in Q1 2024 and bottomed at $1.0 million in Q1 2020.
• The 4-year median for Notes Payables is $39.7 million (2022), against an average of $23.2 million.
• Biggest YoY gain for Notes Payables was 4.38% in 2023; the steepest drop was 4.38% in 2023.
• Year by year, Notes Payables stood at $1.0 million in 2020, then jumped by 3870.6% to $39.7 million in 2022, then increased by 4.38% to $41.4 million in 2023, then grew by 1.08% to $41.9 million in 2024.
• Per Business Quant, the three latest AMRX Notes Payables figures stand at $41.9 million (Q1 2024), $41.4 million (Q4 2023), and $41.0 million (Q3 2023).